Stock Events

ElectroCore 

$6.29
41
+$0.01+0.16% Today

Statistics

Day High
-
Day Low
-
52W High
8.08
52W Low
3.92
Volume
0
Avg. Volume
9,285
Mkt Cap
40.49M
P/E Ratio
-2.28
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.24
-0.85
-0.46
-0.07
Expected EPS
-0.62
Actual EPS
-0.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ECOR. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axonics
AXNX
Mkt Cap3.46B
Axonics, Inc. competes in the neuromodulation market, offering products that could be seen as alternatives to ElectroCore's non-invasive vagus nerve stimulation devices.
LivaNova
LIVN
Mkt Cap2.79B
LivaNova PLC operates in the same space of neuromodulation, providing therapies that could directly compete with ElectroCore's solutions for epilepsy and other neurological conditions.
Inspire Medical Systems
INSP
Mkt Cap4.13B
Inspire Medical Systems, Inc. offers innovative obstructive sleep apnea treatments using nerve stimulation, a direct competitor to ElectroCore's nerve stimulation therapies.
Neogen
NEOG
Mkt Cap3.56B
Neogen Corporation, while primarily focused on food and animal safety, has divisions that explore bioelectronic medicine, potentially overlapping with ElectroCore's market.
Boston Scientific
BSX
Mkt Cap114.22B
Boston Scientific Corporation offers a wide range of medical devices, including neuromodulation products that could serve as alternatives to ElectroCore's technology.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie Inc., through its acquisition of Allergan, has entered the neuromodulation market, potentially competing with ElectroCore's offerings.
Medtronic
MDT
Mkt Cap99.95B
Medtronic PLC provides a broad array of medical devices, including those for neuromodulation, directly competing with ElectroCore's nerve stimulation devices.
Smith & Nephew
SNN
Mkt Cap12.42B
Smith & Nephew plc, while mainly focused on orthopedics, has started exploring the bioelectronic medicine space, which could put it in competition with ElectroCore.
Stryker
SYK
Mkt Cap129.28B
Stryker Corporation's medical technologies, including neurotechnology and spine products, could indirectly compete with ElectroCore by offering different solutions for similar conditions.

Analyst Ratings

15$Average Price Target
The highest estimate is $15.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Electromedical and Electrotherapeutic Apparatus Manufacturing
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Show more...
CEO
Employees
68
Country
US
ISIN
US28531P1030
WKN
000A2N6KT

Listings